Literature DB >> 8407949

Characterization of two forms of human factor Va with different cofactor activities.

J Rosing1, H M Bakker, M C Thomassen, H C Hemker, G Tans.   

Abstract

Factor Va is an essential cofactor in factor Xa-catalyzed prothrombin activation. Purified human factor Va appears to consist of a heavy chain (M(r) approximately 105,000) and a light chain doublet with M(r) approximately 74,000 and approximately 71,000. We separated factor Va by chromatography on a Mono-S column into two fractions, designated factors Va1 and Va2. Factor Va1 contains the light chain with M(r) approximately 74,000, and factor Va2 exclusively contains the light chain with M(r) approximately 71,000. The two forms of factor Va express different cofactor activities when prothrombin is activated at low phospholipid concentrations or on membranes containing low amounts of phosphatidylserine in phosphatidylcholine. Compared with factor Va2, much higher amounts of factor Va1 are required for factor Xa. Va complex formation at the membrane surface. Once incorporated into the prothrombinase complex, factors Va1 and Va2 are equally active in prothrombin activation. This indicates that the two forms of factor Va do not differ in their ability to promote the catalytic activity of factor Xa or to interact with prothrombin. Direct binding experiments show that the different cofactor activities are explained by a greatly impaired ability of factor Va1 to bind to negatively charged membranes. Factor V is also separated into two protein peaks after chromatography on a Mono-S column. Upon incubation with thrombin, the first peak yields factor Va1 and the second peak factor Va2. The same two forms of factor Va were generated when freshly prepared plasma samples or platelet suspensions were treated with thrombin. This shows that the heterogeneity of the light chain domain is an intrinsic property of both plasma and platelet factor V. It is hypothesized that the heterogeneity is caused by small differences in the carboxylterminal C2 domain of factor V that are introduced as the result of post-ribosomal processing.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8407949

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Design of protein membrane interaction inhibitors by virtual ligand screening, proof of concept with the C2 domain of factor V.

Authors:  Kenneth Segers; Olivier Sperandio; Markus Sack; Rainer Fischer; Maria A Miteva; Jan Rosing; Gerry A F Nicolaes; Bruno O Villoutreix
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-23       Impact factor: 11.205

2.  Roles of factor Va heavy and light chains in protein and lipid rearrangements associated with the formation of a bovine factor Va-membrane complex.

Authors:  V Koppaka; W F Talbot; X Zhai; B R Lentz
Journal:  Biophys J       Date:  1997-11       Impact factor: 4.033

3.  Binding of blood coagulation factor VIII and its light chain to phosphatidylserine/phosphatidylcholine bilayers as measured by ellipsometry.

Authors:  J Spaargaren; P L Giesen; M P Janssen; J Voorberg; G M Willems; J A van Mourik
Journal:  Biochem J       Date:  1995-09-01       Impact factor: 3.857

4.  Insights into the complex association of bovine factor Va with acidic-lipid-containing synthetic membranes.

Authors:  G A Cutsforth; V Koppaka; S Krishnaswamy; J R Wu; K G Mann; B R Lentz
Journal:  Biophys J       Date:  1996-06       Impact factor: 4.033

5.  A phosphatidylserine binding site in factor Va C1 domain regulates both assembly and activity of the prothrombinase complex.

Authors:  Rinku Majumder; Mary Ann Quinn-Allen; William H Kane; Barry R Lentz
Journal:  Blood       Date:  2008-06-27       Impact factor: 22.113

6.  Theoretical and experimental study of the D2194G mutation in the C2 domain of coagulation factor V.

Authors:  M A Miteva; J M Brugge; J Rosing; G A F Nicolaes; B O Villoutreix
Journal:  Biophys J       Date:  2004-01       Impact factor: 4.033

7.  Coagulation factor V mediates inhibition of tissue factor signaling by activated protein C in mice.

Authors:  Hai Po H Liang; Edward J Kerschen; Sreemanti Basu; Irene Hernandez; Mark Zogg; Shuang Jia; Martin J Hessner; Raffaella Toso; Alireza R Rezaie; José A Fernández; Rodney M Camire; Wolfram Ruf; John H Griffin; Hartmut Weiler
Journal:  Blood       Date:  2015-09-04       Impact factor: 22.113

8.  Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C.

Authors:  Andrew J Gale; Xiao Xu; Jean-Luc Pellequer; Elizabeth D Getzoff; John H Griffin
Journal:  Protein Sci       Date:  2002-09       Impact factor: 6.725

9.  Comprehensive N- and O-glycosylation mapping of human coagulation factor V.

Authors:  Cheng Ma; Ding Liu; Dong Li; Junping Zhang; Xiao-Qian Xu; He Zhu; Xiu-Feng Wan; Carol H Miao; Barbara A Konkle; Philip Onigman; Weidong Xiao; Lei Li
Journal:  J Thromb Haemost       Date:  2020-06-14       Impact factor: 5.824

Review 10.  Blood coagulation factor Va's key interactive residues and regions for prothrombinase assembly and prothrombin binding.

Authors:  Mark Schreuder; Pieter H Reitsma; Mettine H A Bos
Journal:  J Thromb Haemost       Date:  2019-06-17       Impact factor: 5.824

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.